Search results
Childhood sedentariness may cause premature liver | Newswise
Newswise· 6 days agoBOSTON—Children who are sedentary for more than six waking hours a day have a significantly increased risk of severe fatty liver disease and liver cirrhosis by young adulthood ...
Beware: Sitting Too Much Could Be Harming Kids’ Livers
Mercola· 3 days agoBeware: Sitting Too Much Could Be Harming Kids’ Livers
PSC Partners Announces the First Patient Enrolled Into the WIND-PSC Study, a Global Prospective...
Benzinga· 4 days agoPSC Partners and PSC Partners Canada, both patient-led non-profit organizations supporting education and research in primary sclerosing cholangitis (PSC), announced today the enrollment of the ...
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
Zacks via Yahoo Finance· 17 hours agoOne cohort is evaluating the combination of tobevibart and elebsiran, dosed every four weeks with a...
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
Investor's Business Daily· 3 days agoThe company tested its drug, dubbed VK2809, in patients with nonalcoholic steatohepatitis, or NASH....
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in...
Morningstar· 2 days agoGilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational ...
AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF...
WWTI Watertown· 6 days agoClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 25,...
Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL...
Benzinga· 1 day agoGhent, Belgium – 6 June 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure ...
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in...
Benzinga· 2 days agoGilead Sciences, Inc. GILD, following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational seladelpar ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) and reminds investors ...